Champalimaud Cancer Center

Lisbon 1400-038

1 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of the Pancreas, Multiple Myeloma, Non Hodgkin Lymphoma, Post-Essential Thrombocythemia MF (Post-ET-MF), Post-Polycythemia Vera MF (Post-PV-MF), Primary Myelofibrosis (PMF), Renal Cell Carcinoma

Studies at this site

• Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL — Recruiting now
• Male Breast Cancer: Understanding the Biology for Improved Patient Care — Running, not enrolling
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma — Running, not enrolling
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma — Completed
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) — Completed
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed